Andrea Eleazar, MHS

Data from the KEYNOTE-942 trial confirmed a durable benefit with intismeran plus pembrolizumab among patients with high-risk melanoma.

RAMPART finds durvalumab after kidney cancer surgery cuts recurrence risk but misses DFS significance; combo therapy shines in highest-risk patients.

Results from the phase 3 SUCCESSOR-2 trial showed MeziKd reduced the risk of progression or death by 52% vs Kd in anti–CD38- and LEN-exposed RRMM.

In those with centrally confirmed lymphoma subtypes, the HR for PFS was 0.68, with a 24-month PFS rate of 72.7% vs 62.2% in favor of the tafasitamab combo.

Exploratory data from a phase 3 study may help optimize adjuvant endocrine therapy choices in hormone receptor–positive, HER2-positive breast cancer.

Data may support the strong oncologic outcomes of less invasive surgical options for patients with node-negative disease after neoadjuvant chemotherapy.

The primary end point of GI overall response rate was met with MaaT013 for GI-aGVHD.

Results from the CAMMA 3 trial showed that subcutaneous cevostamab achieved a 52.0% ORR in BCMA-naive relapsed or refractory multiple myeloma.

Data from OptiTROP-Breast02 support sac-TMT as a new treatment option for those with hormone receptor–positive, HER2-negative breast cancer.

A survival analysis stratified by demographic and clinical characteristics revealed an OS benefit was observed with across key subgroups.